Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Type 1 or Type 2 diabetes mellitus.~* Patients who have an expected minimum 50% likelihood of requiring corneal epithelial debridement in the opinion of the Investigator Size of wound should be 8 mm.~* Signed written informed consent by patient or legal guardian.~Exclusion Criteria~* Have current or history of herpetic eye disease in the past 3 years.~* Display evidence of keratitis.~* Have Sjögren's syndrome.~* Have corneal scarring, opacity, or dystrophy.~* Have a history of malignancy.~* Have a history of HIV or AIDs~* Are pregnant or lactating females.~* Are females who can become pregnant.~* Have a known hypersensitivity to the study drug.~* May be regarded as unreliable for the study.~* Have previously participated in this study.~* Experience any complication during the vitrectomy procedure itself, which will exclude the patient from participating in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of eyedrops to the affected eye, identical to the active drug but with no thymosin beta 4 (0.00% thymosin beta 4, w/w), 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
- 1 (Type: ACTIVE_COMPARATOR): There are 2 groups: active drug and placebo. The patients in the active comparator arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).

Based on this trial design, predict the completion outcome and termination type (if applicable).